The American College of Surgeons Oncology Group (ACOSOG) is dedicated to improving the care of the surgical oncology patient through an innovative clinical research program addressing three specific aims: 1. To test novel therapies that may increase response rates and cure rates and reduce morbidities and disabilities associated with cancer care. 2. To conduct basic science studies in conjunction with clinical trials to better understand the biologic basis of diseases and treatments. 3. To support individual members and investigator networks to accrue patients to trials and fulfill the scientific mission of ACOSOG. The scientific portfolio of ACOSOG is focused on investigations specific to molecular and image profiling, neoadjuvant therapies, and targeted or novel surgical therapies. There are four scientific committees including a Basic Science Committee and three disease committees: Breast, Gastrointestinal (GIST, pancreas, and rectum) and Thoracic (lung and esophagus). Three scientific aims are described for ACOSOG trials including: a) to enhance risk stratification by increasing the accuracy of prognostication through imaging and molecular profiling;b) to improve overall response rates and monitor individual responses through the application of neoadjuvant therapies;and c) to investigate novel, targeted, and surgical therapies to maintain oncologic outcomes while Individualized Response Monll reducing toxicities and disabilities thereby improving quality of life. To set the scientific agenda of ACOSOG, the disease committees work with the Basic Science Committee to ensure, where appropriate, the development of science-driven trials. The scientific committees also work closely with the administrative committees &the Peer-Review and Prioritization Committee to ensure membership support as well as prioritization, coordination, and quality science. All disciplines as well as Nursing &Patient Advocates are represented and provide protocol feedback through the Peer-Review Committee process. The Basic Science Committee &ACOSOG Biospecimen Bank ensure the appropriate acquisition and storage of samples to conduct the scientific studies integrated into each clinical trial. To accomplish the scientific aims, ACOSOG conducts clinical trials using an infrastructure consisting of five critical components, including the: 1) Administrative Coordinating Center (ACC or Operations Office) located in Durham, NC within the Duke Clinical Research Institute;2) Biostatistics, located in Rochester, MN, within the Mayo Clinical Cancer Center;3) Leadership, both scientific and organizational;4) Membership and Networks;and 5) the Biospecimen Bank located in St. Louis, MO, within Washington University.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA076001-14
Application #
7758835
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-05-15
Project End
2010-11-30
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
14
Fiscal Year
2010
Total Cost
$3,560,232
Indirect Cost
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Brown, Paul D; Ballman, Karla V; Cerhan, Jane H et al. (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CECĀ·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060
Churilla, Thomas M; Ballman, Karla V; Brown, Paul D et al. (2017) Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. Int J Radiat Oncol Biol Phys 99:1173-1178
Ellis, Matthew J; Suman, Vera J; Hoog, Jeremy et al. (2017) Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol 35:1061-1069
Miller, Christopher A; Gindin, Yevgeniy; Lu, Charles et al. (2016) Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun 7:12498
Haffty, Bruce G; McCall, Linda M; Ballman, Karla V et al. (2016) Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). Int J Radiat Oncol Biol Phys 94:493-502
Brown, Paul D; Jaeckle, Kurt; Ballman, Karla V et al. (2016) Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA 316:401-9
Kent, Michael S; Mandrekar, Sumithra J; Landreneau, Rodney et al. (2016) Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). Ann Thorac Surg 102:230-8
Boughey, Judy C; Ballman, Karla V; Le-Petross, Huong T et al. (2016) Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) Ann Surg 263:802-7
Sikov, William M; Berry, Donald A; Perou, Charles M et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A J Clin Oncol 33:13-21

Showing the most recent 10 out of 65 publications